
Two doses of a pediatric Pfizer-BioNTech COVID-19 vaccine failed to spur an adequate immune response in children aged 2 to 5, the companies announced Friday. That’s a setback for parents hoping to get their youngest children immunized against the new coronavirus as soon as possible. The pediatric trials used a 3 microgram (mcg) dose of… read on > read on >